Nurix therapeutics reports third quarter fiscal 2021 financial results and provides a corporate update

Initiated phase 1 trial of lead cbl-b e3 ligase inhibitor program nx-1607 in patients with cancer
NRIX Ratings Summary
NRIX Quant Ranking